<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04009434</url>
  </required_header>
  <id_info>
    <org_study_id>MITAVI</org_study_id>
    <nct_id>NCT04009434</nct_id>
  </id_info>
  <brief_title>Treatment of Concomitant Mitral Regurgitation by Mitral Valve Clipping in Patients With Successful Transcatheter Aortic Valve Implantation.</brief_title>
  <acronym>MITAVI</acronym>
  <official_title>Treatment of Concomitant Mitral Regurgitation by Mitral Valve Clipping in Patients With Successful Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KKS Dresden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zentrum für Klinische Studien Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether patients after successful transfemoral transcatheter aortic valve
      implantation (TAVI), who have concomitant, moderate to severe mitral regurgitation (MR)
      benefit from an additional treatment of this valve disease as well.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death from any cause and heart failure hospitalization</measure>
    <time_frame>1 year</time_frame>
    <description>Composite endpoint of time to heart failure hospitalization or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death from any cause</measure>
    <time_frame>1, 2, 3, 4 years</time_frame>
    <description>Time from randomization to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for mitral valve reintervention</measure>
    <time_frame>1, 2, 3, 4 years</time_frame>
    <description>Need for mitral valve reintervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral regurgitation severity</measure>
    <time_frame>1 year</time_frame>
    <description>Mitral regurgitation severity at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walk Test</measure>
    <time_frame>1 year</time_frame>
    <description>Change in 6 Minute Walk Test at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association Functional Class</measure>
    <time_frame>1, 3, 6 months and 1, 2, 3, 4 years</time_frame>
    <description>Course of New York Heart Association (NYHA) Functional Class at 1, 3, 6 months and 1, 2, 3, 4 years</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients with AEs, SAEs.</measure>
    <time_frame>1, 2, 3, 4 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1162</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>TAVI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Transfemoral transcatheter aortic valve implantation plus optimal standard of care medical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAVI/MitraClip</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transfemoral transcatheter aortic valve implantation, mitral valve clipping plus optimal standard of care medical therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mitral Valve Clipping</intervention_name>
    <description>Patients receive treatment for mitral regurgitation with mitral valve clipping including standard drug therapy.</description>
    <arm_group_label>TAVI/MitraClip</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAVI</intervention_name>
    <description>Transfemoral transcatheter aortic valve implantation plus optimal standard of care therapy.</description>
    <arm_group_label>TAVI</arm_group_label>
    <arm_group_label>TAVI/MitraClip</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Planned transfemoral TAVI using an Edwards Sapien 3 Transcatheter Heart Valve (or
             subsequent models)

          -  Moderate to severe mitral regurgitation

          -  Symptom status NYHA II-III

          -  Treatment and compliance with optimal, individually-tailored guideline directed
             medical therapy for heart failure for at least 30 days before inclusion

          -  Age ≥ 18 and &lt; 90 years

          -  Written informed consent

        Exclusion criteria

          -  MR mechanism/anatomy precluding MitraClip therapy

          -  Groin blood vessels are not eligible for TAVI procedure

          -  Massive or torrential tricuspid regurgitation

          -  Patients who cannot tolerate procedural anticoagulation or post procedural
             anti-platelet regimen.

          -  Life expectancy &lt; 1 year due to non-cardiac conditions

          -  LVEF ≤ 25%

          -  Hypotension (systolic pressure &lt; 90 mmHg) or requirement of inotropic support or
             mechanical hemodynamic support

          -  Cardiomyopathy other than dilated cardiomyopathy

          -  Fixed pulmonary artery systolic pressure &gt; 70 mm Hg

          -  Any prior mitral valve surgery or transcatheter mitral valve procedure

          -  Stroke or transient ischemic event within 6 months prior to randomization

          -  Severe symptomatic carotid stenosis

          -  Implant or revision of any rhythm management device (CRT or CRT-D) or implantable
             cardioverter defibrillator within 90 days prior to randomization

          -  Untreated clinically significant coronary artery disease requiring revascularization

          -  Any percutaneous cardiac intervention or carotid surgery within the 30 days prior to
             randomization, or any cardiac surgery within six months prior to randomization.

          -  Need for any other cardiovascular surgery (other than MV or AV disease)

          -  Echocardiographic evidence of intracardiac mass, thrombus, or vegetation

          -  Active endocarditis or active infections requiring current antibiotic treatment

          -  Any condition making it unlikely that the patient will be able to complete all
             protocol procedures

          -  Patient unable to provide written informed consent prior to study enrolment

          -  Pregnant or nursing women

          -  Women of child bearing potential

          -  Current participation in any other interventional clinical trial

          -  Patients under legal supervision or guardianship Patients placed in an institution by
             official or court order
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Linke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universitaet Dresden, HEART CENTER</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Axel Linke, MD</last_name>
    <phone>+49 351 4501704</phone>
    <email>mitavi@mailbox.tu-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephan Haussig, MD</last_name>
    <phone>+49 351 4501704</phone>
    <email>mitavi@mailbox.tu-dresden.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart-Center Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Haussig, MD</last_name>
      <phone>+493514501704</phone>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Stenosis</keyword>
  <keyword>Aortic Disease</keyword>
  <keyword>Transcatheter Aortic Valve Implantation</keyword>
  <keyword>Mitral Regurgitation</keyword>
  <keyword>Mitral Valve Regurgitation</keyword>
  <keyword>Mitral Disease</keyword>
  <keyword>Mitral valve clipping</keyword>
  <keyword>MitraClip</keyword>
  <keyword>Heart Valve Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>After publication of the primary objective, the data might be provided to interested scientists on request (e.g. for meta-analyses, health related registers or other scientific questions) in an anonymized way within five years, if the members of the MITAVI-trial group agree.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

